Amylin, amide, rat acetate(124447-81-0,free base)

TargetMol
Product Code: TAR-TP1232L
Supplier: TargetMol
CodeSizePrice
TAR-TP1232L-1mg1mg£308.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1232L-5mg5mg£654.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1232L-10mg10mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1232L-25mg25mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1232L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1232L-100mg100mg£2,295.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Amylin, amide, rat acetate is a potent and high affinity ligand of AMY1 and AMY3 receptors and variably of AMY2 receptors.
CAS:
TP1232L
Formula:
C169H276N52O55S2
Molecular Weight:
3980.45
Pathway:
GPCR/G Protein
Purity:
0.985
SMILES:
[H]N[C@H](C(N[C@H]1CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2CCC[C@H]2C(N[C@H](C(N[C@H](C(N3CCC[C@H]3C(N4CCC[C@H]4C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC5=CC=C(C=C5)O)=O)[C@H](O)C)=O)CC(N)=O)=O)CO)=O)=O)C(C)C)=O)CC(N)=O)=O)[C@H](O)C)=O)=O)=O)CC(C)C)=O)C(C)C)=O)=O)=O)CC(C)C)=O)CC(N)=O)=O)CC(N)=O)=O)CO)=O)CO)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)CC6=CC=CC=C6)=O)CC(N)=O)=O)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)[C@H](O)C)=O)C)=O)NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC1=O)CC(N)=O)=O)=O)C)=O)=O)=O)CCCCN.CC(O)=O
Target:
Amylin Receptor

References

Bower, Rebekah L , Debbie L . Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.